Cargando…
Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated mortality worldwide with an overall five-year survival rate less than 7%. Accumulating evidence has revealed the cancer preventive and therapeutic effects of metformin, one of the most widely prescri...
Autores principales: | Chen, Ke, Qian, Weikun, Jiang, Zhengdong, Cheng, Liang, Li, Jie, Sun, Liankang, Zhou, Cancan, Gao, Luping, Lei, Meng, Yan, Bin, Cao, Junyu, Duan, Wanxing, Ma, Qingyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525317/ https://www.ncbi.nlm.nih.gov/pubmed/28738823 http://dx.doi.org/10.1186/s12943-017-0701-0 |
Ejemplares similares
-
Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway
por: Chen, Ke, et al.
Publicado: (2017) -
YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine
por: Jiang, Zhengdong, et al.
Publicado: (2016) -
Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1
por: Zhou, Cancan, et al.
Publicado: (2018) -
Resveratrol Inhibits ROS-Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR-21
por: Yan, Bin, et al.
Publicado: (2018) -
Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways
por: Cheng, Liang, et al.
Publicado: (2018)